Vials transfer alongside a conveyor on the Novo Nordisk A/S manufacturing services in Hillerod, Denmark, on Monday, June 12, 2023. The success of Novo’s bestsellers Ozempic and Wegovy, medicine that assist individuals lose vital quantities of weight, has created one thing of a gold rush within the pharma business with about 40 firms growing merchandise that may intensify competitors.
Bloomberg | Bloomberg | Getty Pictures
Shares of Denmark’s Zealand Pharma rocketed greater, after the corporate posted robust outcomes from a trial of a liver illness remedy that has been touted as a possible competitor within the booming weight-loss drug market.
The Part 2 trial of the survodutide drug confirmed 83% of adults noticed constructive outcomes for a type of liver irritation attributable to extra fats cells generally known as “MASH,” the corporate stated in an announcement on Monday.
The drug has “demonstrated efficacy” in individuals with weight problems and is at the moment present process 5 Part-3 trials in a scientific program for people who find themselves obese or overweight. It has acquired fast-track designation from the U.S. Meals and Drug Administration.
Analysts latched onto the drug’s doable efficacity in weight problems analysis following the newest check outcomes, which indicated the security of the highest dosage utilized in that trial.
Shares of Zealand Pharma swelled by 30% by 10:53 a.m. London time, amid enthusiasm for the corporate’s potential within the extremely profitable weight problems market that propelled fellow Danish drugmaker Novo Nordisk to change into Europe’s most useful agency on its growth of Ozempic and Wegovy. A number of different companies, together with Eli Lilly, Roche and AstraZeneca, additionally search to compete within the sector.
“Prime-line outcomes demonstrated an enchancment in MASH, in any respect doses explored within the trial. Therapy with survodutide didn’t present surprising security or tolerability points, together with on the greater dose of 6.0 mg,” Michael Novod, head of financial institution Nordea’s healthcare fairness analysis workforce, stated in a Monday be aware, hailing the newest Zealand Pharma outcomes as an “unequivocal win for survodutide.”
“Importantly, the [Phase 2] MASH trial additionally tells us that the 6mg dose is secure, which is the highest dose used within the ongoing [Phase 3] weight problems trial too,” he added.
Analysts at Jefferies assessed that Zeal Pharma’s “place as a key participant in subsequent wave of weight problems therapeutics is underappreciated,” noting the importance of the German co-inventor Boehringer Ingelheim‘s announcement that the drug will advance as “shortly as doable” with remedy on liver illnesses and associated situations.
Pharmaceutical agency Boehringer Ingelheim is funding and working scientific growth of survodutide.
